Cancer Therapeutics Markets

Cancer Therapeutics Markets

Cancer is the second leading cause of death by disease in the United States, exceeded only by heart disease. Traditionally cancer has been treated with surgery, chemotherapy, hormones and radiation therapy, alone or in combination. Emerging technologies include photodynamic therapy, gene therapy, biological therapy (immunotherapy) and angiogenesis inhibitors. Pharmaceutical and biotechnology companies are investing billions of dollars to search out and develop weapons for the arsenal in the war against cancer. This TriMark Publications report provides an overview of the global market for cancer therapeutics. The examination focuses on the efforts of biotechnology companies and pharmaceutical firms to incorporate new technologies for developing anti-cancer drugs into their corporate strategies. This study examines cancer therapeutic products now on the market, as well as those currently under development that might be commercialized in the near future. Additionally, the report profiles a number of firms that are actively involved in marketing and developing of products to be used in the treatment of cancer—both large multinational corporations. The analysis also provides an overview of the disease and data on cancers by site or type. It provides incidence and mortality data for different types of the disease. In addition, the report provides a summary of each of the therapies that are being used to treat cancer. 
 

1. Overview
1.1 Introduction
1.2 Goals & Objectives
1.3 Study Scope and Format
1.4 Methodology
1.5 Information Sources
1.6 Summary of Major Findings

2. Introduction to the Cancer Therapeutic Market

3. Cancer Therapeutics Market Overview
3.1 Cancer Therapeutics in the Pharmaceutical and Biotech Industry .
3.2 Business Analysis of the Cancer Market
3.2.1 Growth Potential
3.2.2 Demographics of Cancer
3.2.3 The Global Market for Cancer Therapies
3.2.3.1 European Cancer Market
3.2.3.2 The Enviroment in the UK for Clinical Research into New Anti-Cancer Therapies .
3.2.3.3 The Suitability of Current UK & EU Regulatory Regimes
3.2.3.4 Comments on the Current EU Regulatory Environment
3.3 The Pharmaceutical Industry
3.4 Cancer Therapies
3.4.1 Market Size
3.5 New Product Trends
3.5.1 Chemotherapy
3.5.2 Hormone Therapy
3.5.3 Photodynamic Therapy and Photosensitizers
3.5.4 Gene Therapy
3.5.4.1 Tumor-Suppressor Gene Therapy
3.5.4.2 Immunomodulatory Gene Therapy
3.5.4.3 Suicide GeneTherapy
3.5.5 Radiation Therapy
3.5.6 Farnesyl Transferase Inhibitors (FTIs)
3.5.7 Genetic Screening
3.5.8 Biological Therapies
3.5.9 Interferons (IFNs)
3.5.10 Interleukins (Ils)
3.5.11 Tumor Necrosis Factor (TNF)
3.5.12 Colony-stimulating Factors (CSFs)
3.5.13 Monoclonal Antibodies (Mabs)
3.5.14 Cancer Vaccines
3.5.15 Antisense Therapy
3.5.16 Adjuvants
3.5.17 Angiogenesis Inhibitors
3.5.17.1 Epidermal Growth Factors (EGFR)
3.5.18 Hypothermia
3.5.19 Transplants
3.5.19.1 Bone Marrow Transplants
3.5.19.2 Stem Cell Transplants

4. The Disease of Cancer
4.1 Incidence of Cancer
4.1.1 United States Statistics
4.1.2 Global Statistics
4.2 Causes of Cancer
4.3 Risk Factors
4.3.1 Smoking
4.3.2 Diet
4.3.3 Radiation
4.3.4 Occupational Risks
4.3.5 Medicine and Infection
4.3.6 Environmental Pollution
4.3.7 Reproduction Factors
4.3.8 Socioeconomic Factors
4.4 Cancer Costs

5. Specific Cancers
5.1 Bladder Cancer
5.1.1 Overview of the Disease
5.1.2 Diagnosis and Staging
5.1.3 Therapy
5.1.4 Drugs in Development
5.2 Brain Cancer
5.2.1 Overview of the Disease
5.2.2 Treatment Options
5.3 Breast Cancer
5.3.1 Overview of the Disease
5.3.2 Therapeutic Drugs
5.3.3 Market Overview for Breast Cancer Therapeutics .
5.4 Cervical Cancer
5.4.1 Overview of the Disease
5.4.2 Treatment Options
5.5 Colon Cancer
5.5.1 Overview of the Disease
5.5.2 Treatment Options
5.5.3 Market Overview for Colon Cancer Therapeutics
5.6 Leukemia
5.6.1 Overview of the Disease
5.6.2 Treatment Options
5.7 Lung Cancer
5.7.1 Overview of the Disease
5.7.2 Treatment Options
5.7.3 Breakthrough Treatments for Lung Cancer
5.7.4 Market Overview for Lung Cancer Therapeutics
5.8 Lymphoma
5.8.1 Overview of the Disease
5.8.2 Treatment Options
5.9 Ovarian Cancer
5.9.1 Overview of the Disease
5.9.2 Treatment Options
5.10 Prostate Cancer
5.10.1 Overview of the Disease
5.10.2 Treatment Options

6. Corporate Profiles
6.1 AstraZeneca
6.2 Aventis
6.3 Bristol-Myers Squibb
6.4 Entremed
6.5 GlaxoSmithKline, plc
6.6 Genentech
6.7 Genta Incorporated
6.8 Ilex Oncology
6.9 Imclone Systems
6.10 ImmunoGen, Inc.
6.11 Eli Lilly & Company
6.12 NaPro Biotherapeutics
6.13 Novartis AG
6.14 Pharmacia Corporaton
6.15 Roche
6.16 Schering-Plough
6.17 Boehringer Ingelheim
6.18 OSI Pharmaceutical
6.19 Abgenix
6.20 Sanofi-Synthelabo
6.21 Millennium Pharmaceuticals

7. Referenced
7.1 On-line References for Cancer
7.2 Print Sources
7.3 Drugs Currently Approved for the Treatment of Cancer
7.4 List of Tables
7.5 FDA Product Approvals for Cancer Indications

List of Tables

Table 1 The 402 Medicines in Development for Cancer 2001
Table 2 Drug Approvals for Cancer Indications Alphabetical Listing June 1996-January 2002
Table 3 New Cancer Therapies in R&D in 2002
Table 4 Opportunities for Molecular-Targeting Therapeutics for Cancer
Table 5 Top U.S. Biotechnology Companies by Market Capitalization
Table 6 Top Pharmaceutical Companies by Market Capitalization
Table 7 Clinical Development for Hoffmann-La Roche
Table 8 Genentech, Inc. Oncology Pipeline
Table 9 Breakdown of Cytostatic Market by Company
Table 10 Health Spending Cancer Rates
Table 11 Spending on Health by Country
Table 12 Annual Spending on Cancer Drugs per Person
Table 13 Patients per Cancer Specialist
Table 14 World Healthcare Cancer Theratpuritc Market by Region
Table 15 The Projected Growth in the US Market for Cancer Therapeutics
Table 16 The Projected Growth in the European Market for Cancer Therapeutics.
Table 17 The Projected Growth in the Japanese Market for Cancer Therapeutics.
Table 18 Revenues for Cancer Therapeutics in the United States (in millions) 1997-1999
Table 19 Developmental Cancer Vaccines
Table 20 Antiangiogenic Drugs in Clinical Trial for Cancer
Table 21 Estimates of New Cancer Cases and Deaths in the United States by Sex for All Cancer Sites 2001
Table 22 Estimates for the Leading Sites of New Cancer Cases and Deaths in the United States by Sex 2001
Table 23 Estimated Worldwide Number of New Cancer Cases and Deaths by Type of Cancer 
Table 24 Estimated Number of New Cancer Cases and Deaths by Region 
Table 25 Cancer Death Rates per 100,000 Population (and Rank) for All Cancer Sites by Country 1992-1995
Table 26 Genes and Cancer Risk
Table 27 Carcinogens in the Workplace
Table 28 Drugs Used in Bladder Cancer Therapy
Table 29 Drugs in Development for Bladder Cancer
Table 30 Medicines in Development for Brain Cancer
Table 31 Classes of Chemotherapy Drugs Used to Treat Breast Cancer
Table 31A U.S. Sales of Doxyrubicin
Table 32 New Therapeutics for Breast Cancer
Table 33 Herceptin Worldwide Sales 2000-2005
Table 34 Classes of Drugs Used to Treat Breast Cancer
Table 35 Aromatase Inhibitors 
Table 36 Worldwide Estimated AstraZenica's Nolvadex Sales 2002-2005
Table 37 Worldwide Sales Estimates for Arimidex
Table 38 Innovative Drug Therapies Applied to the Breast Cancer Market Sector
Table 38 A Treatment Regimens for Advanced Breast Cancer
Table 39 Medicines in Development for Cervical Cancer
Table 40 New Therapies for Colon Cancer
Table 40A Camptosar Worldwide and U.S. Sales
Table 41 Estimated Worldwide Sales for Xeloda 2001-2005
Table 42 Estimated Worldwide Sales of Tomudex 1998-2005
Table 43 Medicines in Development for Leukemia
Table 44 Pricing of Novartis' Gleevec in Various Contries
Table 45 Estimated US Sales of Rituxan, 1999-2005
Table 46 Cytotoxics for Lung Cancer Therapy
Table 47 Anti-angiogenics for Lung Cancer
Table 48 Drugs in Development for Lung Cancer
Table 49 Medicines in Development for Lymphoma
Table 50 Current Therapies for Ovarian Cancer
Table 51 Emerging Therapies for Ovarian Cancer
Table 52 New Development Therapies for Ovarian Cancer
Table 53 New Drug Types for Ovarian Cancer
Table 54 Medicines in Development for Prostate Cancer List of Tables